Leadership Corporate Leaders

More

  • The new CEO's made some moves, but not enough.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • chantix.jpg

    I had planned to blog about the nearly unanimous bearish analyst commentary this morning after Genentech's earnings report yesterday. The biotech giant beat on earnings per share, but came up short on Street expectations for sales of its top four drugs. DNA shares are under pressure again today.

  • In the wake of Pfizer pulling the plug on its poor-selling inhaled insulin Exubera, the world's biggest diabetes drug company, Novo Nordisk is throwing in the towel on development of its version of inhaled insulin.

  • A Congressional committee said on Monday it invited current and former chief executives of three major financial institutions -- Countrywide Financial Corp , Citigroup  and Merrill Lynch  -- to testify on Feb. 7 about their severance packages.

  • pharmasmarket_enhance.jpg

    The highly anticipated results of the study that goes by the acronym "ENHANCE" are out this morning. You can see what it stands for in the companies' press release. (I wonder how many meetings and brainstorming sessions go into coming up with some of the industry's clinical trial acronyms and abbreviations.)

  • Everyone should have a gold stock in their portfolio, Cramer says, now more than ever. He speaks to the CEO of his favorite.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Walt Disney President and Chief Executive Robert Iger received a 7 percent increase in total compensation in fiscal 2007, to $27.7 million, according to a filing with the U.S. Securities and Exchange Commission Friday.

  • Countrywide's headquarters in Los Angeles.

    I'm outside Countrywide headquarters this morning, where employees have a mixture of relief and worry. Countrywide has already laid off 11,000 people, but it's certain that more will eventually have to go. Bank of America won't need everyone. This could affect everyone from bank tellers to the corporate pilots (Countrywide has not one but two Gulf Streams).

  • Cramer often tells Homegamers to be wary when a new CEO takes the helm of a company. This is the exception to the rule. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • shell_logo_new.jpg

    Royal Dutch Shell execs have been talking about the impact of high oil prices on future energy projects--but the company continues to press on with plans despite headwinds facing the sector. “Increasing supply is best way to affect the price,” says Shell Oil President John Hofmeister.

  • Merrill Lynch & Co is seeking to hire Thomas Montag, who retired as one of Goldman Sachs co-heads of global securities trading last month, according to financial sources.

  • In a long-expected move, discount retailer Target said Wednesday that Chairman and Chief Executive Bob Ulrich will retire May 1 and be replaced by President Gregg Steinhafel.

  • Former American International Group Chief Executive Maurice "Hank" Greenberg said that a group he represents currently does not intend to solicit proxies from AIG shareholders, buy more AIG shares, or initiate a tender offer for the company.

  • After significant writedowns and a top level shakeup at the company, is there more trouble ahead for Bearn Stearns? The new CEO, Alan Schwartz, doesn't think so ... but he's not giving guarantees.

  • Even with new CEOs, these stocks should not be touched, Cramer says. They are intrinsically broken.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Jimmy Cayne's departure isn't quite enough for the beleagured Bear, Cramer says. It'll need to take a page out of Merrill's playbook to get back on track.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • New CEO Howard Schultz called Cramer to personally promise a turnaround. Cramer believes he can deliver.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • AMGEN

    So, imagine my surprise when Amgen put out a press release this morning with new financial guidance. You can read it for yourself here. The release was issued in conjunction with the company's presentation at the JPMorgan Healthcare Conference.

  • James Cayne

    Bear Stearns' management shake-up could make the investment bank a takeover target, but the specter of more write-downs might keep suitors on the sidelines.

  • isis_genziyme.jpg

    After the closing bell Monday, Genzyme and Isis Pharmaceuticals announced a blockbuster deal that set the overcrowded halls abuzz here at the JPMorgan Healthcare Conference. They're partnering on an Isis drug in late-stage development for cholesterol. It's a once-a-week injectable for people who don't get their cholesterol low enough taking a statin like Lipitor, Crestor or Zocor.